{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-042800","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.676852+00:00","generated_at":"2026-06-04T01:06:40.104150+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Candel presents second enLIGHTEN candidate at AACR; induces TLS, enhances anti-PD-1 in mice","bullets":["Second multimodal immunotherapy candidate from enLIGHTEN platform targets tertiary lymphoid structures (TLS) in solid tumors.","Two payload combinations, predicted via enLIGHTEN analytics, induced TLS, monotherapy anti-tumor activity, and boosted anti-PD-1 response in mouse models.","Milestone accelerated from Q3 2024 to April 2024, validating platform speed.","TLS induction is a novel strategy to improve anti-tumor immunity; data presented at AACR April 5-10, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-042800","json":"https://secwatch.observer/filing/0000950170-24-042800.json","markdown":"https://secwatch.observer/filing/0000950170-24-042800.md","text":"https://secwatch.observer/filing/0000950170-24-042800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024042800/0000950170-24-042800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017024042800/cadl-20240409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:06:40.104150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}